Michele A. Grimbaldeston

8.1k total citations · 2 hit papers
77 papers, 6.2k citations indexed

About

Michele A. Grimbaldeston is a scholar working on Immunology, Dermatology and Molecular Biology. According to data from OpenAlex, Michele A. Grimbaldeston has authored 77 papers receiving a total of 6.2k indexed citations (citations by other indexed papers that have themselves been cited), including 55 papers in Immunology, 21 papers in Dermatology and 16 papers in Molecular Biology. Recurrent topics in Michele A. Grimbaldeston's work include Mast cells and histamine (38 papers), Asthma and respiratory diseases (15 papers) and Dermatology and Skin Diseases (13 papers). Michele A. Grimbaldeston is often cited by papers focused on Mast cells and histamine (38 papers), Asthma and respiratory diseases (15 papers) and Dermatology and Skin Diseases (13 papers). Michele A. Grimbaldeston collaborates with scholars based in Australia, United States and United Kingdom. Michele A. Grimbaldeston's co-authors include Stephen J. Galli, Mindy Tsai, Adrian M. Piliponsky, Janet Kalesnikoff, Prue H. Hart, John J. Finlay‐Jones, Cara Williams, Ching‐Cheng Chen, Susumu Nakae and Angel F. López and has published in prestigious journals such as Nature, Proceedings of the National Academy of Sciences and Journal of Biological Chemistry.

In The Last Decade

Michele A. Grimbaldeston

70 papers receiving 6.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

MAST CELLS AS “TUNABLE” EFFECTOR AND IMMUNOREGULATORY CELLS: Recent Advances

2005 1.0k citations Stephen J. Galli, Janet Kalesnikoff et al. profile →
Immunomodulatory mast cells: negative, as well as positive, regulators of immunity

2008 595 citations Stephen J. Galli, Michele A. Grimbaldeston et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Michele A. Grimbaldeston Australia	37	4.5k	1.6k	1.5k	1.2k	987	77	6.2k
Adrian M. Piliponsky United States	33	4.0k 0.9×	2.3k 1.5×	2.0k 1.4×	1.1k 0.9×	637 0.6×	58	6.2k
Yoseph A. Mekori Israel	36	3.7k 0.8×	1.5k 0.9×	1.7k 1.1×	1.4k 1.2×	425 0.4×	147	6.0k
Michael F. Gurish United States	55	6.0k 1.3×	2.2k 1.4×	2.3k 1.6×	1.8k 1.5×	655 0.7×	103	8.3k
Yoshimichi Okayama Japan	41	4.1k 0.9×	2.4k 1.5×	1.7k 1.2×	767 0.7×	635 0.6×	127	5.9k
Silvia Bulfone‐Paus Germany	45	4.0k 0.9×	749 0.5×	665 0.5×	966 0.8×	893 0.9×	127	6.1k
Hajime Suto Japan	31	2.5k 0.6×	1.4k 0.9×	1.3k 0.9×	479 0.4×	1.5k 1.5×	58	4.6k
Tetsuya Honda Japan	37	2.4k 0.5×	991 0.6×	1.3k 0.9×	819 0.7×	2.7k 2.7×	133	5.5k
D D Metcalfe United States	35	4.2k 0.9×	1.5k 1.0×	1.8k 1.2×	1.3k 1.1×	317 0.3×	81	5.7k
George H. Caughey United States	59	5.3k 1.2×	2.3k 1.4×	2.1k 1.4×	2.7k 2.3×	477 0.5×	134	10.1k
Hiroo Yokozeki Japan	32	1.7k 0.4×	1.1k 0.7×	997 0.7×	617 0.5×	1.5k 1.5×	238	4.4k

Countries citing papers authored by Michele A. Grimbaldeston

Since Specialization

Citations

This map shows the geographic impact of Michele A. Grimbaldeston's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michele A. Grimbaldeston with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michele A. Grimbaldeston more than expected).

Fields of papers citing papers by Michele A. Grimbaldeston

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michele A. Grimbaldeston. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michele A. Grimbaldeston. The network helps show where Michele A. Grimbaldeston may publish in the future.

Co-authorship network of co-authors of Michele A. Grimbaldeston

This figure shows the co-authorship network connecting the top 25 collaborators of Michele A. Grimbaldeston. A scholar is included among the top collaborators of Michele A. Grimbaldeston based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michele A. Grimbaldeston. Michele A. Grimbaldeston is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Greening, Neil, Christopher E. Brightling, Ruth Tal‐Singer, et al.. (2025). S1 Randomised, placebo-controlled trial of astegolimab for COPD with frequent exacerbations: ALIENTO. A7.1–A7.

Zhang, Wenhui, Dorothy Cheung, Alice Fong, et al.. (2025). Safety, Pharmacokinetics, and Immunogenicity of Astegolimab, an Anti‐ST2 Monoclonal Antibody, in Randomized, Phase I Clinical Studies. Clinical and Translational Science. 18(10). e70338–e70338.

Faiz, Alen, Jorine E. Hartman, Corry‐Anke Brandsma, et al.. (2025). Genome-Wide Differential Airway Gene Expression Analysis Identifies Genes Associated with COPD Comorbidities. Lung. 203(1). 58–58.

Choy, David F., Evgeniya V. Nazarova, Michele A. Grimbaldeston, et al.. (2024). A Stop-gain in FUT2 Associates With Several COPD Related Phenotypes and Clinical Outcomes. A2788–A2788.

Bell, Laura C., David F. Choy, Petr Novotný, et al.. (2024). Post Hoc Analysis of Quantitative HRCT Imaging Parameters in Astegolimab (anti-ST2) Treated COPD Patients Associates Airway Wall Thickness With Clinical Outcomes. A1204–A1204.

Zhang, Wenhui, Dorothy Cheung, Alice Fong, et al.. (2024). Pharmacokinetics (PK) of the anti-ST2 monoclonal antibody, astegolimab. PA2987–PA2987. 2 indexed citations

Grimbaldeston, Michele A., et al.. (2023). SIALIC ACID AND PERCENT-SOLIDS: SIMPLE AND REPRODUCIBLE BIOMARKERS OF AIRWAY MUCUS HYDRATION IN CF AND COPD. CHEST Journal. 164(4). A6520–A6520.

Calderón, Ariel A., et al.. (2023). Targeting interleukin-33 and thymic stromal lymphopoietin pathways for novel pulmonary therapeutics in asthma and COPD. European Respiratory Review. 32(167). 220144–220144. 66 indexed citations

Yip, Kwok Ho, Harshita Pant, William Smith, et al.. (2023). IgE receptor of mast cells signals mediator release and inflammation via adaptor protein 14-3-3ζ. Journal of Allergy and Clinical Immunology. 152(3). 725–735.e10. 4 indexed citations

10.

Maurer, Marcus, Dorothy Cheung, Xiaoying Yang, et al.. (2022). Phase 2 randomized clinical trial of astegolimab in patients with moderate to severe atopic dermatitis. Journal of Allergy and Clinical Immunology. 150(6). 1517–1524. 43 indexed citations

11.

Mai, Elaine, Braeden K. Ego, Jack Bevers, et al.. (2021). Development of an ultra-sensitive human IL-33 biomarker assay for age-related macular degeneration and asthma drug development. Journal of Translational Medicine. 19(1). 517–517. 3 indexed citations

12.

Cildir, Gökhan, John Toubia, Kwok Ho Yip, et al.. (2019). Genome-wide Analyses of Chromatin State in Human Mast Cells Reveal Molecular Drivers and Mediators of Allergic and Inflammatory Diseases. Immunity. 51(5). 949–965.e6. 48 indexed citations

13.

Reber, Laurent L., Riccardo Sibilano, Philipp Starkl, et al.. (2017). Imaging protective mast cells in living mice during severe contact hypersensitivity. JCI Insight. 2(9). 44 indexed citations

14.

Hercus, Timothy R., Sophie E. Broughton, Paul G. Ekert, et al.. (2012). The GM-CSF receptor family: Mechanism of activation and implications for disease. Growth Factors. 30(2). 63–75. 56 indexed citations

15.

Yu, Chunping, et al.. (2010). Evidence that vitamin D3 promotes mast cell–dependent reduction of chronic UVB-induced skin pathology in mice. The Journal of Experimental Medicine. 207(3). 455–463. 90 indexed citations

16.

Piliponsky, Adrian M., Ching‐Cheng Chen, Michele A. Grimbaldeston, et al.. (2009). Mast Cell-Derived TNF Can Exacerbate Mortality during Severe Bacterial Infections in C57BL/6-Kit Mice. American Journal Of Pathology. 176(2). 926–938. 116 indexed citations

17.

Grimbaldeston, Michele A., et al.. (2005). Mast Cell-Deficient W-sash c-kit Mutant KitW-sh/W-sh Mice as a Model for Investigating Mast Cell Biology in Vivo. American Journal Of Pathology. 167(3). 835–848. 486 indexed citations

18.

Hart, Prue H., Scott L. Townley, Michele A. Grimbaldeston, Zeinab G. Khalil, & John J. Finlay‐Jones. (2002). Mast cells, neuropeptides, histamine, and prostaglandins in UV-induced systemic immunosuppression. Methods. 28(1). 79–89. 65 indexed citations

19.

Hart, Prue H., Michele A. Grimbaldeston, & John J. Finlay‐Jones. (2001). Sunlight, Immunosuppression And Skin Cancer: Role Of Histamine And Mast Cells. Clinical and Experimental Pharmacology and Physiology. 28(1-2). 1–8. 70 indexed citations

20.

Grimbaldeston, Michele A., Lone Skov, Ole Baadsgaard, et al.. (2000). High Dermal Mast Cell Prevalence is a Predisposing Factor for Basal Cell Carcinoma in Humans. Journal of Investigative Dermatology. 115(2). 317–320. 36 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact